<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>研发客 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-16T12:16:30+08:00</updated>
  <subtitle>《研发客》公众号由上海汐潮信息技术有限公司提供，行业资深中英文独立编辑记者创办。我们观察药物创新生态，报道临床研究与监管科学。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>传奇：Cilta-cel疗法总缓解率96.9% | 大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/z1jo4DA4yZ8M1XLpmckgvA</id>
    <link href="https://mp.weixin.qq.com/s/z1jo4DA4yZ8M1XLpmckgvA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>康方：超越联合疗法的双IO靶点双抗｜大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/LY9VxIHG3XDcGG3FJx-lfg</id>
    <link href="https://mp.weixin.qq.com/s/LY9VxIHG3XDcGG3FJx-lfg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>科望：一年一分子｜大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/u_keaC8RnsOXR4z87p0nkQ</id>
    <link href="https://mp.weixin.qq.com/s/u_keaC8RnsOXR4z87p0nkQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>智飞：结核领域有所斩获｜大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/RS6JFz1o8Xg9jsG_ZbqGEQ</id>
    <link href="https://mp.weixin.qq.com/s/RS6JFz1o8Xg9jsG_ZbqGEQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>嘉和：CDK4/6抑制剂可能同类最优 | 大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/4A8lBMw0ucHmXb0wOl0d1Q</id>
    <link href="https://mp.weixin.qq.com/s/4A8lBMw0ucHmXb0wOl0d1Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>再鼎：合作项目着眼全球未满足临床需求 | 大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/jvK3aSbP31ifB98P4FUMFQ</id>
    <link href="https://mp.weixin.qq.com/s/jvK3aSbP31ifB98P4FUMFQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>信达：信迪利今年在美递交BLA | 大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/at4pdEsWGJQvlI70lofdnQ</id>
    <link href="https://mp.weixin.qq.com/s/at4pdEsWGJQvlI70lofdnQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>君实：特瑞普利单抗有望成为最快在美上市的国产PD-1｜大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/Im03yAHG7nYJ5yFgNFKZxg</id>
    <link href="https://mp.weixin.qq.com/s/Im03yAHG7nYJ5yFgNFKZxg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>授权交易逾百，中国创新药研发进入新时代 | 年度</title>
    <updated>2021-01-14T23:51:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/TYzLgUmstuFBEO7xMxtSEA</id>
    <link href="https://mp.weixin.qq.com/s/TYzLgUmstuFBEO7xMxtSEA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>亦诺微：OvPENS平台，溶瘤病毒创新研发的“永动机”｜大话JPM</title>
    <updated>2021-01-14T23:51:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/8kuPUaRUQJo97mrGdHXtkw</id>
    <link href="https://mp.weixin.qq.com/s/8kuPUaRUQJo97mrGdHXtkw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>科越医药：首款补体药本月进临床 | 大话JPM</title>
    <updated>2021-01-14T23:51:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/lehG37j8pnGUnmU4WH8prA</id>
    <link href="https://mp.weixin.qq.com/s/lehG37j8pnGUnmU4WH8prA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>亚盛医药：与艾伯维竞争Bcl-2｜大话JPM</title>
    <updated>2021-01-14T23:51:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/9Ih2NjEdL_akE1zDtjzQew</id>
    <link href="https://mp.weixin.qq.com/s/9Ih2NjEdL_akE1zDtjzQew" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>三生制药：押宝 HER2 ｜大话JPM</title>
    <updated>2021-01-14T23:51:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/JDvvjRIyj67FWxq72xZ5cQ</id>
    <link href="https://mp.weixin.qq.com/s/JDvvjRIyj67FWxq72xZ5cQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>德琪医药：从引进到自建管线｜大话JPM</title>
    <updated>2021-01-14T23:51:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/MLSuKgVsquEWh-qbM8GC7g</id>
    <link href="https://mp.weixin.qq.com/s/MLSuKgVsquEWh-qbM8GC7g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>和黄医药：最大突破来自海外上市 | 大话JPM</title>
    <updated>2021-01-14T23:51:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/MZvydQJ5Gh7lt8lNQ0l9Qg</id>
    <link href="https://mp.weixin.qq.com/s/MZvydQJ5Gh7lt8lNQ0l9Qg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>摩根大通全球医疗健康峰会举办  参会中国企业增多 | 新闻稿</title>
    <updated>2021-01-14T23:51:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/9LhXe_RyVvUfZ667BJd7OA</id>
    <link href="https://mp.weixin.qq.com/s/9LhXe_RyVvUfZ667BJd7OA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新药研发领域资本狂欢年 | 年度</title>
    <updated>2021-01-13T21:21:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/G0oVgVvnjN9Cd-YgwDr77A</id>
    <link href="https://mp.weixin.qq.com/s/G0oVgVvnjN9Cd-YgwDr77A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复宏汉霖达雷妥尤单抗类似药正式获批临床｜新闻稿</title>
    <updated>2021-01-13T21:21:34+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/lUrvNdr7cy8xT1XuYpX81Q</id>
    <link href="https://mp.weixin.qq.com/s/lUrvNdr7cy8xT1XuYpX81Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>康宁杰瑞：开启后双抗时代｜江湖</title>
    <updated>2021-01-12T22:25:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/AHZF6nIE_anH6Bn1_9igVw</id>
    <link href="https://mp.weixin.qq.com/s/AHZF6nIE_anH6Bn1_9igVw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>创响王健：Borderless Innovation——中国迈入全球合作2.0时代 | 江湖</title>
    <updated>2021-01-10T22:32:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-10:/s/bZzw-9_TagW9jU231mTsrw</id>
    <link href="https://mp.weixin.qq.com/s/bZzw-9_TagW9jU231mTsrw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>